Boston Scientific's endoscope business grows by over 20 percent

Although endoscope sales at US-based Boston Scientific have had a good year in 2021, the company has seen its bottom line halved during its latest financial year.

Like Danish company Ambu, US-based Boston Scientific sells devices for endoscopy | Photo: Ambu / PR

In 2021, Boston Scientific added 20.3 percent to its endoscopy business, and sold endoscopes for USD 2.14bn, compared to 2020’s result of USD 1.78bn, the company reports in its full-year 2021 financial report.

Accounting for currency fluctuations, that equates to a 18.9-percent growth in the company’s endoscopy division, and Boston Scientific has a revenue of USD 11.88bn and a growth in the entire group of 18.7 percent after currency fluctuations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs